GURUFOCUS.COM » STOCK LIST » USA » NAS » VistaGen Therapeutics Inc (NAS:VTGN) » Definitions » GF Score
Switch to:

VistaGen Therapeutics GF Score

: 31/100 (As of Today)
View and export this data going back to 2011. Start your Free Trial

VistaGen Therapeutics has the GF Score of 31, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 5/10
2. Profitability Rank : 1/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 2/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes VistaGen Therapeutics might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Competitive Comparison

For the Biotechnology subindustry, VistaGen Therapeutics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

VistaGen Therapeutics GF Score Distribution

For the Biotechnology industry and Healthcare sector, VistaGen Therapeutics's GF Score distribution charts can be found below:

* The bar in red indicates where VistaGen Therapeutics's GF Score falls into.



VistaGen Therapeutics  (NAS:VTGN) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.


VistaGen Therapeutics GF Score Related Terms

Thank you for viewing the detailed overview of VistaGen Therapeutics's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.


VistaGen Therapeutics Business Description

VistaGen Therapeutics logo
Traded in Other Exchanges
N/A
Address
343 Allerton Avenue, South San Francisco, CA, USA, 94080
VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.
Executives
Adler Reid G. officer: CHIEF LEGAL OFFICER C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVE. SOUTH SAN FRANCISCO CA 94090
Fitzpatrick Margaret M director C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVE. SOUTH SAN FRANCISCO CA 94080
Rotunno Mary L. director C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVE. SOUTH SAN FRANCISCO CA 94090
Curley Joanne director C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVE SOUTH SAN FRANCISCO CA 94080
Ginski Mark J officer: SENIOR VP, HEAD OF CMC 12119 CECILIA CT KINGSVILLE MD 21087
Cunningham Ann Michelle director 255 N CALDWELL CIRCLE DOWNINGTOWN PA 19335
Mcpartland Mark A. officer: VP Corporate Development C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Smith Mark Alan officer: CHIEF MEDICAL OFFICER 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Gin Jerry B director 343 ALLERTON AVE SOUTH SAN FRANCISCO CA 94080
Dotson Jerrold Duane officer: ACTING CFO 5 CENTERPOINTE DRIVE SUITE 400 LAKE OSWEGO OR 97035
Underdown Brian J. director C/O LUMIRA CAPITAL INVESTMENT MANAGEMENT 141 ADELAIDE ST. WEST, SUITE 770 TORONTO ONTARIO CANADA M5H 3L5 A6 00000
Bonfiglio Gregory A. director 384 OYSTER POINT BOULEVARD, NO. 8 SOUTH SAN FRANCISCO CA 94080
Platinum Long Term Growth Vii, Llc 10 percent owner 152 WEST 57TH STREET 4TH FLOOR NEW YORK NY 10019
Rice A. Franklin officer: CHIEF FINANCIAL OFFICER 384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080
Cato Allen Easley 10 percent owner 4364 SOUTH ALSTON AVENUE DURHAM NC 27713

VistaGen Therapeutics Headlines

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)